Novel Adamantane–Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells
Molecules · 12.12.2025 · 30 (24) · 4756
DOI: 10.3390/molecules30244756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 12.12.2025. Verfasst von Ema Lupšić und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108…. Hauptthemen laut MEDLINE: Glioblastoma, Adamantane, Drug Resistance, Neoplasm, Reactive Oxygen Species. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
Multidrug resistance (MDR) presents a significant challenge in the treatment of glioblastoma. We evaluated six novel adamantane–sclareol hybrids that integrate a natural labdane diterpene scaffold with an adamantane moiety to address this issue. Compounds 2, 5, and 6 demonstrated the ability to bypass P-glycoprotein (P-gp)-mediated resistance in resistant U87-TxR cells and induced collateral sensitivity, with compound 2 exhibiting the highest selectivity for glioblastoma compared to normal glial cells. Mechanistic studies revealed that compounds 2 and 5 selectively triggered early apoptosis in MDR cells, significantly elevated levels of H2O2 and peroxynitrite, and disrupted mitochondrial membrane potential. Additionally, these compounds altered the expression of key genes involved in glutathione (GSH) and thioredoxin (Trx) antioxidant defense systems and increased ASK1 protein levels, indicating the activation of ROS-driven apoptotic signaling. Both compounds inhibited P-gp function, leading to enhanced intracellular accumulation of rhodamine 123 (Rho 123) and synergistically sensitized U87-TxR cells to paclitaxel (PTX). A preliminary Rag1 xenograft study demonstrated that compound 5 effectively suppressed tumor growth without causing significant weight loss. Collectively, these findings position adamantane–sclareol hybrids, particularly compounds 2 and 5, as promising strategies that exploit an MDR-associated reactive oxygen species (ROS) vulnerability, combining selective cytotoxicity, redox disruption, and P-gp modulation to eliminate resistant glioblastoma cells and enhance the efficacy of chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108 Belgrade, Serbia.
- University of Belgrade-Faculty of Chemistry, P.O. Box 51, Studentski Trg 16, 11158 Belgrade, Serbia.
- University of Belgrade-Institute of Chemistry, Technology, and Metallurgy, National Institute of the Republic of Serbia, Njegoševa 12, 11000 Belgrade, Serbia.
- Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Panepistimiou 3 (Biopolis), 41500 Larissa, Greece.
ORCID-Profile: Ema Lupšić, Pavle Stojković, Marija Grozdanić, Nataša Terzić-Jovanović, Milica Pajović, Milica Pešić, Ana Podolski-Renić
Förderung
- Science Fund of the Republic of Serbia
Zitieren
APA
Lupšić, E., Stojković, P., Grozdanić, M., Terzić-Jovanović, N., Pajović, M., Koutsougianni, F., Alexopoulou, D., Opsenica, I. M., Pešić, M., & Podolski-Renić, A. (2025). Novel Adamantane–Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells. Molecules, 30(24), 4756. https://doi.org/10.3390/molecules30244756
Vancouver
Lupšić E, Stojković P, Grozdanić M, Terzić-Jovanović N, Pajović M, Koutsougianni F, et al. Novel Adamantane–Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells. Molecules. 2025;30(24):4756. doi:10.3390/molecules30244756
BibTeX
@article{Lupi2025,
author = {Lupšić, Ema and Stojković, Pavle and Grozdanić, Marija and Terzić-Jovanović, Nataša and Pajović, Milica and Koutsougianni, Fani and Alexopoulou, Dimitra and Opsenica, Igor M and Pešić, Milica and Podolski-Renić, Ana},
title = {Novel Adamantane–Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells},
journal = {Molecules},
year = {2025},
volume = {30},
number = {24},
pages = {4756},
doi = {10.3390/molecules30244756}
}
EUVIMED